Table 3 Lung function and ventilation
From: Inhaled β-agonist does not modify sympathetic activity in patients with COPD
FEV1[L] | FVC [L] | FRC [L] | FRC (helium dilution) [L] | TLC [L] | RV [L] | Respiratory rate [/min] | Tidal volume [mL] | Respiratory minute volume [mL/min] | |
|---|---|---|---|---|---|---|---|---|---|
Visit 1 (Week 0) | Mean ± SD; p (two-sided) | ||||||||
Baseline | 1.35 ± 0.46 | 2.60 ± 0.69 | 4.65 ± 1.33 | 3.64 ± 0.97 | 6.61 ± 1.39 | 3.90 ± 1.28 | 15.66 ± 3.34 | 549 ± 200 | 8362 ± 3333 |
After salmeterol | 1.31 ± 0.40 | 2.58 ± 0.62 | 3.86 ± 1.68 | 3.21 ± 0.78 | 5.88 ± 1.89 | 3.16 ± 1.64 | 15.17 ± 3.45 | 610 ± 250; | 8934 ± 3942 |
Change ‘after salmeterol’ – Baseline | -0.04 ± 0.23; p = 0.35 | -0.02 ± 0.35; p = 0.72 | -0.90 ± 1.66; p < 0.01 | -0.52 ± 0.73; p < 0.01 | -0.82 ± 1.71; p = 0.01 | -0.85 ± 1.79; p = 0.01 | -0.49 ± 1.62; p = 0.09 | 60 ± 118; p = 0.01 | 572 ± 1530; p = 0.05 |
Visit 2 (Week 4) | |||||||||
Before salmeterol | 1.38 ± 0.44 | 2.68 ± 0.64 | 4.20 ± 1.61 | 3.57 ± 0.86 | 6.23 ± 1.70 | 3.46 ± 1.61 | 15.76 ± 3.74 | 564 ± 197 | 8773 ± 3369 |
After salmeterol | 1.32 ± 0.46 | 2.64 ± 0.71 | 3.67 ± 1.80 | 3.38 ± 0.77 | 5.67 ± 1.83 | 2.90 ± 1.79 | 15.48 ± 4.02 | 593 ± 217 | 8829 ± 3629 |
Change ‘after salmeterol’ – Baseline | -0.04 ± 0.21; p = 0.33 | 0.04 ± 0.35; p = 0.51 | -1.26 ± 1.75; p < 0.01 | -0.27 ± 0.83; p = 0.18 | -1.17 ± 1.84; p < 0.01 | -1.30 ± 1.80; p < 0.01 | -0.06 ± 2.63; p = 0.90 | 56 ± 184; p = 0.15 | 671 ± 2963; p = 0.28 |